Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (PSTV) announced a poster presentation at the 6th Biennial Pediatric Neuro-Oncology Research Conference. The poster focuses on a Phase I study of Rhenium-186 Nanoliposomes (186RNL) for treating ependymoma and high-grade glioma. Dr. Ashley S. Plant-Fox from Northwestern University leads the presentation. The FDA has provided positive feedback on their study synopsis and confirmed no additional toxicology studies are needed for pediatric trials. RNL has also received Orphan Drug and Fast Track designations for glioblastoma treatment.
AUSTIN, Texas, June 9, 2021 – Plus Therapeutics (Nasdaq: PSTV) has announced that President and CEO Marc H. Hedrick M.D. will participate in the BIO Digital Conference on June 10-11 and 14-18, 2021. The conference presentation will be accessible on-demand on the conference website. Following the event, it will also be available in the Investors section of Plus Therapeutics' website. The company focuses on nanoliposome-encapsulated radionuclides for cancer treatment, enhancing drug delivery and efficacy for rare cancers.
Plus Therapeutics (PSTV) announced two collaboration agreements aimed at advancing the cGMP manufacturing processes for Rhenium NanoLiposome (RNL™), targeting recurrent glioblastoma. The partnerships include Invicro LLC for process development and imaging support, and Eurofins BioPharma for developing test methods for purity and compliance. These agreements are crucial for progressing RNL™ to registrational clinical trials and eventual commercial supply, according to CEO Marc H. Hedrick. Previous agreements include a master services engagement with Piramal Pharma Solutions for RNL™ production.
Plus Therapeutics, Inc. (Nasdaq: PSTV) reported first-quarter financial results for 2021, highlighting a cash balance of $14.4 million, up from $8.3 million at year-end 2020. The company posted a net loss of $2.7 million, or $(0.33) per share, compared to a net loss of $1.1 million, or $(0.28) per share, in Q1 2020. Key developments include advancements in their lead drug Rhenium NanoLiposome (RNL™) for treating rare cancers, and progress in clinical trials, including treatment for recurrent glioblastoma and upcoming FDA meetings. A conference call is scheduled for April 22, 2021, at 5:00 p.m. ET.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on therapies for rare cancers, will report its first quarter 2021 financial results on April 22, 2021, after market close. Following the earnings announcement, a conference call and webcast will take place at 5:00 PM ET to discuss results and provide a corporate update. Plus Therapeutics utilizes a unique nanotechnology platform aimed at enhancing drug delivery and efficacy for difficult-to-treat cancers. Details for the conference call and webcast are available on their website.
Plus Therapeutics (Nasdaq: PSTV) has signed a master services agreement (MSA) with Piramal Pharma Solutions for the development of its Rhenium NanoLiposome (RNL™), aimed at treating rare cancers, including glioblastoma. The agreement entails transferring analytical and microbiological methods, production processes, and stability studies, executed at Piramal's facility in Lexington, Kentucky. This partnership is expected to pave the way for future clinical and commercial supply agreements. The collaboration marks a significant milestone in advancing RNL towards regulatory approval.
Plus Therapeutics (Nasdaq: PSTV) announced that CEO Marc Hedrick will present at two upcoming virtual conferences. The first event is the BIO-Europe Spring Digital 2021 from March 22-25, with presentations available on demand starting March 22. The second event is the Q1 Virtual Investor Summit, taking place March 23-25, with a scheduled presentation on March 23 at 11:30 a.m. ET. Investors interested in meetings should contact conference coordinators. Webcasts will be available on Plus Therapeutics' website under 'Events' in the Investor Relations section.
Plus Therapeutics (Nasdaq: PSTV) has announced that Marc Hedrick, M.D., the Company’s President and CEO, will present at two upcoming virtual conferences. The first is the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, with the presentation available on demand starting March 9. The second is the Maxim Emerging Growth Conference on March 17-18, 2021, with on-demand access beginning March 17. Investors interested in meetings can contact conference coordinators. For more details, visit PlusTherapeutics.com.
Plus Therapeutics (PSTV) reported financial results for Q4 and FY 2020, highlighting significant clinical advancements in the ReSPECT™ Phase 1 trial for recurrent glioblastoma. The company completed its sixth dosing cohort and showcased positive interim data, supported by a NIH/NCI grant. As of Dec 31, 2020, cash reserves stood at $8.3 million, down from $17.6 million the previous year. The net loss for 2020 was $8.2 million, improving from $11.4 million in 2019. Plus Therapeutics aims to advance its CNS oncology portfolio and expand its pipeline in 2021.
Plus Therapeutics (Nasdaq: PSTV) will report its fourth quarter and full year 2020 financial results on February 22, 2021, after market close. A conference call will follow at 5:00 PM ET for a discussion of the results and corporate update. The company focuses on developing targeted treatments for rare cancers utilizing nanotechnology to enhance drug delivery and efficacy. Interested parties can access a live webcast and subsequent replay on their investor relations website.